Analysis on clinical study registration characteristics of traditional medicine for the treatment of type 2 diabetes mellitus based on the international clinical trials registry platform
Jiaqi Chai,Yumeng Tan,Hui Zhao,Tiancai Wen,Wenyuan Xu,Ning Liang,Sihong Yang,Xinghua Xiang,Dezhao Kong,Lijiao Yan,Huifang Zhang
DOI: https://doi.org/10.1097/gscm.0000000000000025
2024-07-24
Abstract:This study analyzes clinical trials of traditional medicine (including Chinese herbal medicine and non-pharmacological therapies) for the treatment of type 2 diabetes mellitus (T2DM) registered in the International Clinical Trials Registry Platform (ICTRP), and accordingly explores their clinical trial registration characteristics, development trend and intervention status, in an attempt to provide references for future research design, diagnosis and management of traditional Chinese medicine (TCM) therapy for T2DM.
The clinical trials related to Chinese herbal medicine and non-pharmacological therapies for treating T2DM were retrieved on the ICTRP online from the time of database construction to August 13, 2023 to analyze the time of registration, country and institution of the study, source of funding, type and design of the study, randomization and blinding methods, clinical staging, therapeutic measures, and main therapeutic effect indexes. Descriptive statistical analysis was performed using R4.3.0 and Excel softwares.
A total of 774 clinical trials for T2DM treatment were included, of which 127 were traditional herbal therapies and 647 were non-pharmacological therapies. The T2DM clinical trial registration institutions were distributed in 50 countries worldwide involving 15 clinical registration platforms, with the most registrations in Iran, China and Australia, and the top three registration platforms were the Iranian Clinical Trial Registry (IRCT), the Australian New Zealand Clinical Trials Registry (ANZCTR) and the ICTRP. Universities (551, 71.19%) were the main funding sources. Intervention studies (750, 96.90%) were the primary study type, including randomized controlled trials (432, 56. 4%), and 225 studies mentioned the blinding method. 530 trials (68.48%) with the sample size ≤ 100 were included. Study phases were predominantly phase II and phase III (108, 51.43%). The interventions of traditional medicine for T2DM were composed of Chinese herbal medicines (mainly ginseng and astragalus compound), non-pharmacological therapies (mainly exercise and diet therapies), and two or more comprehensive treatment regime. According to the type of study design, the first three main therapeutic indexes were fasting blood glucose (286 times), glycated hemoglobin (282 times) and insulin resistance (120 times), and the top three secondary therapeutic indexes were BMI (179 times), fasting blood glucose (175 times), and glycated hemoglobin (134 times).
The study dissects the current status and trend of registration of clinical trials on traditional medicine for T2DM treatment. The number of trial registrations is on the rise year by year, and there are obvious geographical differences in the countries and platforms of registration. The trial design is mainly randomized controlled blind trials with a sample size of less than 100, and the main interventions are non-pharmacological therapies. Correct and standardized registration of clinical trials and timely reporting of study results are greatly important to facilitate the implementation of clinical trials, reduce publication bias, provide high-level diagnostic and therapeutic bases for clinical practice guidelines and develop effective treatment strategies. This study is expected to help other scholars, healthcare professionals, patients and the public to understand the latest research trends and hotspots in this field, and provide certain references and inspirations for the future research design and clinical practice of TCM in the treatment of T2DM.
Medicine